Atlanta

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Depression2 trials
• Fibromyalgia2 trials
• Narcolepsy2 trials
• Hidradenitis suppurativa1 trial
• Insomnia1 trial

Phase

• Phase 37 trials
• Phase 41 trial

Status

• Recruiting4 trials
• Completed2 trials
• Enrolling by invitation1 trial
• Terminated1 trial

Lead sponsor

• Axsome Therapeutics, Inc.7 trials
• ACELYRIN Inc.1 trial

Running trials

• Enrolling by invitation

  Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia

  NCT07637162· Phase 3· Axsome Therapeutics, Inc.· Source

• Recruiting

  Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

  NCT07484217· Phase 3· Axsome Therapeutics, Inc.· Source

  Contact: Study Director

• Recruiting

  Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

  NCT07398417· Phase 3· Axsome Therapeutics, Inc.· Source

  Contact: Study Director

• Recruiting

  Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

  NCT06568367· Phase 3· Axsome Therapeutics, Inc.· Source

  Contact: Study Director

• Recruiting

  A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

  NCT06223880· Phase 4· Axsome Therapeutics, Inc.· Source

  Contact: Study Director

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Depression2 recruiting
• Fibromyalgia2 recruiting
• Insomnia1 recruiting

Closed trials

• Terminated

  Hidradenitis Suppurativa Study of Izokibep

  NCT05905783· Phase 3· ACELYRIN Inc.· Source

• Completed

  A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)

  NCT05113745· Phase 3· Axsome Therapeutics, Inc.· Source

• Completed

  A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy

  NCT05059223· Phase 3· Axsome Therapeutics, Inc.· Source